恢复支链氨基酸分解代谢可改善临床前心血管-肾脏-代谢综合征模型的肾功能
在两种临床前心血管-肾脏-代谢(CKM)综合征模型(ZSF1肥胖大鼠和单肾切除SDT脂肪大鼠高盐水饮水)中,BCAA分解代谢受损与CKM相关且可能为其原因,BDK抑制剂BT2改善尿蛋白、肾脏肥大和病理,与恩格列净联用有附加效应。
要点
- 在ZSF1肥胖大鼠肾脏中证实BCAA分解代谢受损。
- BT2改善两种CKM模型的尿蛋白含量、肾脏肥大和肾脏病理。
- BT2与恩格列净联用对肾脏参数、基因表达和线粒体有附加改善。
核心结论
- 研究表明,BDK抑制除既往报道的代谢和心脏功能益处外,还可能改善肾脏健康,或成为CKM的新治疗途径。
研究设计与样本
- 使用两种临床前CKM模型:贪食性ZSF1肥胖大鼠和单肾切除SDT脂肪大鼠(高盐水饮水)。
- 应用无偏蛋白质组学、转录组学和代谢组学分析评估整体肾脏基因表达和线粒体功能。
主要发现
- BCAA分解代谢受损与CKM相关且可能为其原因,并在ZSF1肥胖大鼠肾脏中证实BCAA分解代谢受损。
- 在两种CKM动物模型中,BDK抑制剂BT2治疗改善了尿蛋白含量、肾脏肥大和肾脏病理。
- BT2与钠-葡萄糖协同转运蛋白2抑制剂恩格列净联用对改善肾脏参数、肾脏基因表达特征及肾脏线粒体密度和功能表现出附加效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with metabolic syndrome and heart failure (HF) often have accompanying kidney dysfunction, which was recently defined as cardiovascular-kidney-metabolic (CKM) syndrome. Prior metabolomics profiling of metabolic syndrome patients identified a plasma branched chain amino acid (BCAA) signature, and BCAAs themselves are elevated in the myocardium of patients with HF, potentially due to a defect in BCAA catabolic breakdown. The rate limiting step of BCAA catabolism is the decarboxylation by the enzyme branched chain ketoacid dehydrogenase (BCKDH), which is negatively regulated by BCKDH kinase (BCKDK or BDK), and BDK inhibitors improve metabolism and heart failure preclinically. METHODS: Here, using two pre-clinical CKM models, the hyperphagic ZSF1 obese rat and the uninephrectomized SDT fatty rat with high salt drinking water, we applied unbiased proteomic, transcriptomic and metabolomic profiling to assess overall kidney gene expression and mitochondrial function. RESULTS: We show that BCAA catabolic impairment is associated with and may be causal to CKM and demonstrated impairment in BCAA catabolism within ZSF1 obese rat kidneys. In both CKM animal models, treatment with the BDK inhibitor BT2 improved urine protein content, kidney hypertrophy, and kidney pathology. Furthermore, coadministration of BT2 and the sodium-glucose cotransporter-2 inhibitor empagliflozin demonstrated additive effects to improve kidney parameters, kidney gene expression signatures, and kidney mitochondrial density and function. CONCLUSIONS: Our study suggests that in addition to its previously reported beneficial effects on metabolism and cardiac function, BDK inhibition may also improve kidney health and therefore could represent a new therapeutic avenue for CKM.
引用
- Bollinger E, Williams G, Piper ME, et al. Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models. Kidney Int. 2025. PMID: 40409667. doi:10.1016/j.kint.2025.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。